



BRITISH SOCIETY FOR HAEMOSTASIS AND THROMBOSIS

# Annual Scientific Meeting 2023

**Novel therapeutics & emerging technology in  
haemostasis & thrombosis**

*Wednesday 25 – Friday 27 January*

Edgbaston Park Hotel & Conference Centre, Birmingham

# Programme

**[bsht.org.uk/meetings-events/](https://bsht.org.uk/meetings-events/)**

**Registered Office:** Slade & Cooper Ltd, Beehive Mill, Jersey St, Ancoats, Manchester M4 6JG  
**Registered charity No:** 282204



BRITISH SOCIETY FOR HAEMOSTASIS AND THROMBOSIS

## About the BSHT:

The British Society for Haemostasis and Thrombosis (BSHT) is our national organisation for health-care professionals and researchers with an interest in the science of blood coagulation and its associated diseases. We are always open to applications for membership from individuals interested in joining us and details are available at our website.

**Membership is only £25 per year**

<https://bsht.org.uk/>

## Benefits of Membership:

- Reduced registration rates at our Annual Scientific Meeting (see below)
- Access to bursaries
- Travel awards to support attendance at other meetings
- Access to funding for undergraduate research projects
- Voting rights at the Annual General Meeting

**Apply for membership:**

<https://bsht.org.uk/membership/>

## Annual Scientific Meeting:

Each year the Society hosts an Annual Scientific Meeting that is the largest in the UK focusing specifically on haemostasis and thrombosis. It provides a forum for clinicians, researchers and industry representatives to come together to share knowledge of the latest developments and ideas for new innovations.

The meeting is headlined with invited state-of-the-art plenaries from global experts in the fields of haemostasis and thrombosis to meet the continuing professional development needs of attendees. The format is specifically designed to encourage trainees from all professional groups to submit their work to gain valuable experience of presenting in a friendly environment before doing so on larger, international stages. Sessions with talks from established key opinion leaders are tailored to the educational needs of scientific and clinical trainees.

**Contact:**

<https://bsht.org.uk/>

With grateful thanks to this year's sponsors, who make this meeting possible

PLATINUM  
+  
SYMPO  
SPONSOR



*AstraZeneca has provided a sponsorship grant towards this independent Programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence, except for the AstraZeneca sponsored symposia presentation.*

PLATINUM



GOLD



SILVER



---

**Disclaimer:**

The BSHT ASM is sponsored by various companies as listed above.

These organisations have had no input into the development of the conference programme, or influenced the choice of speakers.

This excludes the sponsored symposia session where the programme is developed and speakers identified by the sponsor.

Sponsoring organisations will not be contributing in any way to the organisation and running of any social activities around the conference period.

# Contents

- Welcome from the BSHT President
- Members of the BSHT committee and Board
- Useful information
- Venue floor plans
- Programme
- Exhibitor and sponsor company information

## See additional files for

- Plenary speaker presentation summaries and biographies
- Clinical Education session speaker presentation summaries and biographies
- Scientists in Training abstracts
- Emerging Fellows abstracts
- Summer student abstracts
- Oral communication abstracts
- Poster abstracts
- ECR speaker biographies
- ECR speaker handouts
- ECR – proposed e banner
- Sponsored symposium speaker biographies
- Attendee list

# Welcome from the BSHT President

26 January 2023

Dear Colleagues,

On behalf of the Committee, it is a wonderful pleasure to welcome you to the 2023 Annual Scientific Meeting of the British Society for Haemostasis and Thrombosis in Birmingham at the Edgbaston Park Hotel & Conference Centre. Having shed the covid complications of the last few years we are delighted to be in person again, although were slightly worried regarding travel with the current train strikes!

I want to thank the speakers, participants, committee members, Wheldon Events and particularly Natasha for her patience and extreme hard work over the last few months to pull together a wonderful meeting. Our national congress is an excellent opportunity to engage with our friendly and inspiring haemostasis and thrombosis community, share experiences and forge new collaborations. This meeting continues to offer a platform for younger members and we are delighted to see the return of the Early Career Evening to provide additional training and mentoring opportunities for these members. We were pleased to welcome Dr Claire Whyte to the BSHT committee as an ECR member and look forward to growing this aspect in future years.

As always, the BSHT is exceptionally grateful to our industry sponsors for their continued support and participation. Please do take the time to visit their stands and discover more about the many interesting innovations that are available to enhance your scientific and clinical activities.

Finally, we welcome your thoughts and input on the BSHT meeting, the website and additional initiatives. Please do share your thoughts with committee members and take the opportunity to complete the post-meeting survey.

Thank you for your valued participation in the BSHT. Please enjoy the meeting and the opportunity to interact with friends and colleagues.

Very best,

A handwritten signature in black ink, appearing to read 'Nicola J Mutch', with a large, sweeping flourish extending to the right.

**Dr Nicola J Mutch**

President of the British Society for Haemostasis and Thrombosis

# Members of the BSHT committee and board

<b>Prof Nicola Mutch</b>	<i>President</i>
<b>Dr Catherine Bagot</b>	<i>Secretary</i>
<b>Prof Neil Morgan</b>	<i>Treasurer</i>
<b>Prof Helen Philippou</b>	<i>Scientific Secretary</i>

Dr Josefin Ahnström  
Prof Robert Ariens  
Dr Jim Crawley  
Dr Nicola Curry  
Dr Cédric Duval  
Dr Keith Gomez  
Dr Laura Green  
Associate Professor Craig Hughes  
Prof Mike Laffan  
Dr Isabelle Salles-Crawley  
Prof Henry Watson

## **ECR committee representative**

Dr Claire Whyte

# REGISTER NOW



## ISTH 2023

JUNE 24-28 CONGRESS

#ISTH2023 ISTH2023.ORG

 **montréal**

# JOIN US IN MONTRÉAL

## JUNE 24-28, 2023

Plan to attend the ISTH 2023 Congress, the premier scientific and networking event for healthcare professionals in thrombosis and hemostasis.

**ISTH2023.ORG**

**#ISTH2023**

## Useful information

### Certificate of attendance

If you require a certificate of attendance please let the team on the registration desk know and this will be emailed to you after the meeting.

Please remember to sign the register daily on your arrival.

Do complete the meeting evaluation in order to get your certificate.

<https://www.surveymonkey.co.uk/r/BSHT2023>

The evaluation will close on Monday 13 February at 23:30 hrs

### Exhibition

The following companies are represented in the exhibition area. Please take time to visit the stands.

<b>PLATINUM</b>	AstraZeneca   LFB Biopharmaceuticals Limited
<b>GOLD</b>	Pfizer   Sysmex UK Ltd
<b>SILVER</b>	CSL Behring   Frontiers in Cardiovascular Medicine   Octapharma   Quadratach Diagnostics Limited   Sobi   Stago UK Ltd   Werfen Ltd   ZACROS

### Meeting details

<b>BSHT committee meeting</b>	Lloyd Suite ( <i>Hornton Grange</i> ) committee members only
<b>ECR session</b>	Hornton Grange lounge
<b>Faculty networking evening</b>	Lloyd Suite ( <i>Hornton Grange</i> ) invited guests only
<b>Registration desk</b>	Fry Lounge ( <i>ground floor</i> )
<b>Refreshments   Exhibition</b>	Writers Suite ( <i>1<sup>st</sup> floor</i> )
<b>Main meeting space</b>	Fry Suite ( <i>ground floor</i> )
<b>Clinical Education session</b>	Pevsner Suite ( <i>1<sup>st</sup> floor</i> )
<b>Posters   Networking Reception</b>	Composers Suite ( <i>1<sup>st</sup> floor</i> )
<b>Networking event (<i>Thursday</i>)</b>	Lloyd Suite ( <i>Hornton Grange</i> ) – booked guests only
<b>Accommodation</b>	Edgbaston Park Hotel & Conference Centre <u>Check in:</u> from 15:00 hrs   <u>Check out:</u> from 11:00 hrs
<b>Luggage Store</b>	Luggage and coats can be left in the Fry Lounge

### Poster session


The poster session will be held in the Composers Suite on the first floor on Thursday between 18:45 – 19:45 hrs

### WiFi


Enabled throughout.



## Floor plans | Ground floor



# Floor plans | First floor



# Programme | Wednesday 25 January

15:00 – 18:00	<b>BSHT committee meeting</b>	<i>Lloyd Room - Hornton Grange</i>
18:15 – 20:15	<p><b>ECR session - Career chats on the couch</b></p> <p>An informal opportunity to meet and network with other early career researchers' and hear informal career development talks. Combining talks with panel discussion and opportunity for discussion with the audience.</p> <p>Organised and hosted by: <a href="#">Dr Claire Whyte</a></p>	<i>Lounge - Hornton Grange</i>
18:15	Finger buffet served ( <i>ECR participants only</i> )	
18:30 – 19:15	<p><b>Panel starts</b></p> <p>18:30 – 19:15 Introduction by <a href="#">Dr Claire Whyte</a></p> <p><b>ISTH training Fellowship – Propelling your research with a laboratory exchange</b> <i>Outlining the application process and benefits of partaking in a laboratory exchange</i> <a href="#">Dr Harriet Allan</a> (London)</p> <p><b>Vice-Chair BHF Fellowships panel – What makes a strong Fellowship application?</b> <i>Navigating the ECR path to a research fellowship application</i> <a href="#">Prof Jules Hancox</a> (Bristol)</p> <p><b>The pros and cons of academia vs industry</b> <i>So many career options for scientists in the 21st century: how do you figure out which one is the best for you?</i> <a href="#">Prof Anna Randi</a> (London)</p> <p><b>Getting the work life balance</b> <i>The impossible task of fitting everything into 24 hours</i> <a href="#">Dr Josefin Ahnström</a> (London)</p> <p>19:15 – 19:45 Panel discussion</p> <p>19:45 – 20:15 Discussion on ECR webpage and ECR banner</p>	
19:30	<b>Faculty networking evening</b> ( <i>invited guests only</i> )	<i>Lloyd Room - Hornton Grange</i>

# Programme | Thursday 26 January

07:00 onwards	Breakfast ( <i>residents only</i> )	<i>1900 Restaurant</i>
08:30 – 10:00	Registration	<i>Fry Lounge</i>
08:45 – 10:00	Refreshments   Networking   Exhibition	<i>Writers Suite - 1st floor</i>
10:00 – 10:10	<b>Welcome + Introduction</b> <b>Prof Nikki Mutch</b> (BSHT President)	<i>Fry Suite - Ground floor</i>
10:10 – 12:00	<b>SESSION ONE   Plenary 1 and Oral Communications 1</b> Chair   <b>Prof Mike Laffan</b>	
10:10 – 10:45	<b>Plenary 1</b> <b>Venous thromboembolism in cancer patients</b> <b>Prof Ingrid Pabinger-Fasching</b> , Medical University of Vienna	
	<b>Oral Communications 1</b> Co-chairs   <b>Prof Nikki Mutch + Dr Alex Bye</b>	
10:45 – 11:00	OC 1 Impact of thromboprophylaxis on hospital acquired thrombosis following hospital discharge in patients admitted with COVID-19 <b>Deepa J Arachchillage</b> (London)	
11:00 – 11:15	OC HMB-001 – a novel bispecific antibody accumulating and targeting endogenous FVIIa to activated platelets supports enhanced haemostatic responses in models of Glanzmann thrombasthenia <b>Minka Zivkovic</b> (Utrecht, The Netherlands)	
11:15 – 11:30	OC 3 Recombinant von willebrand factor (vonvendi) mediates reversal of platelet dysfunction induced by antiplatelet agents <b>Alex Bye</b> (London)	
11:30 – 11:45	OC 4 A microfluidic assay to investigate thrombogenesis in TTP patients <b>Adela Constantinescu-Bercu</b> (London)	
11:45 – 12:00	OC 5 Localisation and function of plasminogen within the thrombus milieu <b>Claire Whyte</b> (Aberdeen)	
12:00 – 12:30	<b>BSHT AGM</b>	<i>Fry Suite - Ground floor</i>
12:00 – 13:20	Lunch   Networking   Exhibition <i>Writers Suite -1st floor</i>	

# Programme | Thursday 26 January

13:20 – 15:10	<b>SESSION TWO   Plenary 2 and Scientists in Training</b> Chair   <a href="#">Dr Josefin Ahnström</a>	<i>Fry Suite - ground floor</i>
13:20 – 13:55	<b>Plenary 2</b> <b>New links between immunity and blood coagulation</b> <a href="#">Dr Roger Preston</a> , Royal College of Surgeons in Ireland, Dublin, Ireland	
	<b>Scientists in Training</b> Co-chairs   <a href="#">Dr Isabelle Salles</a> + <a href="#">Dr Claire Whyte</a>	
13:55 – 14:10	1. A microfluidic model to study the initiating events in venous thrombosis <a href="#">Laura Mereweather</a> (London)	
14:10 – 14:25	2. Antibodies are a key component in Salmonella induced platelet aggregation <a href="#">Rachel Lamerton</a> (Birmingham)	
14:25 – 14:40	3. Inflamed Endothelial Cells Reduce Clot Surface Fibrin Film Coverage <a href="#">Ghadir Alkarithi</a> (Leeds)	
14:40 – 14:55	4. Reprogramming of glucose metabolism in murine platelets in type 1 diabetes <a href="#">Reem N Alotaibi</a> (Leeds)	
14:55 – 15:10	5. Cytokines stimulate expression and release of plasminogen activator inhibitor-1 (PAI-1) from endothelial cells <a href="#">Steven Humphreys</a> (Aberdeen)	
15:10 – 15:40	Refreshments   Networking   Exhibition	<i>Writers Suite -1st floor</i>
15:40 – 17:45	<b>SESSION THREE   Plenary 3 and Emerging Fellows</b> Chair   <a href="#">Dr Nikki Curry</a>	<i>Fry Suite - ground floor</i>
15:40 – 16:15	<b>Plenary 3</b> <b>Low VWF – a bleeding disorder of unknown cause</b> <a href="#">Prof James O'Donnell</a> , Irish Centre for Vascular Biology, RCSI	
	<b>Emerging Fellows</b> Co-chairs   <a href="#">Prof Jim Crawley</a> + <a href="#">Dr Adela Constantinescu-Bercu</a>	
16:15 – 16:40	<b>Pro-thrombotic clot phenotype – potential for novel therapeutic targets and repurposing of agents</b> <a href="#">Dr Julia Sandrin Gauer</a> (University of Leeds)	
16:40 – 17:05	<b>HaemSTAR: Empowering the next generation of clinical haematology researchers</b> <a href="#">Dr Pip Nicolson</a> (University of Birmingham)	

# Programme | Thursday 26 January

17:05 – 17:30	<b>Endothelial injury in the antiphospholipid syndrome</b> Dr Charis Pericleous (Imperial College, London)
17:30 – 17:55	<b>Evolving Pathophysiological and Clinical Care Considerations in iTTP</b> Dr Rebecca Shaw (University of Liverpool)
17:55 – 18:45	Comfort break
18:45 – 19:45	<p><b>Poster session + networking</b> <i>Composers Suite - 1st floor</i></p> <p>Posters Po1 - Po14 – see poster folder for abstracts</p> <p>Po1 Endothelial cells delay fibrin clot lysis under static conditions in vitro Jerjes Abu-Hanna (Oxford)</p> <p>Po2 Altered fibrinolytic potential in antiphospholipid syndrome Deepa J Arachchilage (London)</p> <p>Po3 Real-world experience with a human fibrinogen concentrate: clinical data from adult and paediatric patients requiring fibrinogen for bleeding control and prevention Chafké Belmokhtar (Le Plessis Robinson, France)</p> <p>Po4 Ligand-induced clustering of CLEC-2 is governed by ligand valency, receptor density and Syk Joanne Clark (Birmingham)</p> <p>Po5 The potential of tumour-associated tissue factor mRNA measurement as a predictor of the risk of pulmonary embolism Camille Ettelaie (Hull)</p> <p>Po6 Tissue factor acts as a gauge for the level of injury by regulating the balance of expression of p16INKa and p21CIP1/WAF1 cell -cycle regulators Sophie Featherby (Hull)</p> <p>Po7 Tissue Factor (TF) and factor VII modulate the cell phenotype and are potential indicators of malignancy in pancreatic cystic lesions Farzana Haque (Hull) <i>presented by Sophie Featherby</i></p> <p>Po8 Investigating endothelial cell Pim kinase as a novel anti-thrombotic target Eima Karim (Burton on Trent)</p>

# Programme | Thursday 26 January

18:45 – 19:45	<p><b>Poster session + networking</b> Posters P01 - P014 – see poster folder for abstracts</p> <p>P09 Generation of multivalent nanobodies to probe cluster-induced platelet receptor activation <a href="#">Eleya Martin</a> (Birmingham)</p> <p>P010 FIX is localised in the vessel wall and can generate thrombin when in complex with collagen IV <a href="#">Gael Morrow</a> (Oxford)</p> <p>P011 Mathematical models of thrombin generation: A unified approach. <a href="#">Matt J. Owen</a> (Burton on Trent)</p> <p>P012 Post-infusion monitoring of Afstyla FVIII replacement therapy – data from the UK National External Quality assessment for Blood Coagulation (UK NEQAS BC) programme 2022 <a href="#">Christopher Reilly-Stitt</a> (Sheffield)</p> <p>P013 NEQAS Blood Coagulation trials platelet pools to launch a platelet EQA programme for Light Transmission Aggregometry <a href="#">Christopher Reilly-Stitt</a> (Sheffield)</p> <p>P014 Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing major cytoreductive surgery: Results from a randomised, controlled Phase 2 study <a href="#">Sophia Stanford</a> (Basingstoke)</p>	<i>Composers Suite - 1st floor</i>
19:45 – 22:30	Networking evening ( <i>pre booked attendees only</i> )	<i>Lloyd Suite - Hornton Grange</i>

---

**Please let us have your feedback about this meeting!**



<https://www.surveymonkey.co.uk/r/BSHT2023>

The evaluation will close on Monday 13 February at 23:30 hrs

---

## **Certificate of attendance**

Please complete the evaluation in order to receive your certificate of attendance.



# Programme | Friday 27 January

07:00 onwards	Breakfast ( <i>residents only</i> )	<i>1900 Restaurant</i>
07:45 – 08:30	Registration	<i>Fry Lounge</i>
08:00 – 08:30	Refreshments   Networking   Exhibition	<i>Writers Suite - 1st floor</i>
08:30 – 11:00	<b>SESSION FOUR   Plenary 4 and Oral Communications 2   Sponsored symposium</b> <i>Fry Suite - ground floor</i>	
	Chair   <a href="#">Prof Neil Morgan</a>	
08:30 – 09:05	<b>Plenary 4</b> <b>Platelet receptor clustering and signalling</b> <a href="#">Dr Natalie Poulter</a> , University of Birmingham	
09:05 – 09:55	<p><b>Sponsored symposium</b></p> <div data-bbox="450 853 944 1014" data-label="Image"> </div> <p><b>DOAC reversal and the management of major bleeds</b> Chair: <a href="#">Professor Mike Laffan</a></p> <p>Speakers: <b>Practical application of DOAC reversal in the emergency setting</b> <a href="#">Professor Raza Alikhan</a></p> <p><b>Acute Management of an Uncontrollable or Life-Threatening Gastrointestinal Bleeds Including Reversal of Anticoagulation</b> <a href="#">Dr Vinay Sehgal</a></p> <p><i>This is a promotional symposium sponsored and organised by AstraZeneca</i></p>	
09:55 – 10:00	Transfer to parallel session	

# Programme | Friday 27 January

10:00 – 11:00	<p><b>Clinical Education Session – Part 1</b></p> <p>Organised and chaired by   <a href="#">Dr Gillian Lowe</a></p> <p>10:00 - 10:30  <b>Common Clinical Dilemmas in Management of APS</b>  <a href="#">Dr Karen Breen</a>, Guy's and St Thomas' NHSFT</p> <p>10:30 - 10:40 Case study 1  <b>Acquired Glanzmann's Thrombasthenia with IgG and IgA against activated aIIbb<sub>3</sub></b>  <a href="#">Dr Adela Constantinescu-Bercu</a> (Postdoctoral Research Fellow University College London)</p> <p>10:40 - 10:50 Case study 2  <b>Acquired Haemophilia A in the COVID era – building the case for Emicizumab?</b>  <a href="#">Dr Christina Crossette-Thambiah</a> (Haematology Specialist Registrar, Imperial College London)</p> <p>10:50 - 11:00 Case study 3  <b>A challenging case of refractory ITP in and after pregnancy</b>  <a href="#">Dr Eman Hassan</a> (University Hospitals of Birmingham)</p>	<i>Pevsner Room - 1st floor</i>
<p><b>Oral Communications 2</b></p> <p>Co-chairs   <a href="#">Dr Craig Hughes</a> + <a href="#">Dr Samantha Montague</a></p>		<i>Fry Suite - ground floor</i>
10:00 – 10:15	<p>OC 6  NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome hyperactivation in megakaryocyte lineage induces anemia and enhances the inflammatory response in mice  <a href="#">Alex Brill</a> (Birmingham)</p>	
10:15 – 10:30	<p>OC 7  Pim kinase: A novel regulator of platelet and megakaryocyte thromboxane A<sub>2</sub> and C-X-C-R motif receptors  <a href="#">Sophie Nock</a> (Manchester)</p>	
10:30 – 10:45	<p>OC 8  Analysis of TFPI<math>\alpha</math> Anticoagulant Function In Vivo  <a href="#">Anastasis Petri</a> (London)</p>	
10:45 – 11:00	<p>OC 9  Analysis of the Protein S - TFPI<math>\alpha</math> Anticoagulant Pathway In Vivo  <a href="#">Parvathy Sasikumar</a> (London)</p>	
11:00 – 11:20	Refreshments   Networking   Exhibition	<i>Writers Suite - 1st floor</i>

# Programme | Friday 27 January

11:20 – 12:20	<b>Clinical Education Session – Part 2</b> <i>Pevsner Room - 1st floor</i>  11:20 - 11:30 Case study 4 <b>Running low on adrenaline</b> <a href="#">Dr Marcin Lubowiecki</a> (Specialist Registrar in Haematology Oxford University Hospitals NHS Foundation Trust)  11:30 - 11:40 Case study 5 <b>A case of coagulation testing disparity in alcohol related hepatitis</b> <a href="#">Dr Andrew Preston</a> (LAT3, Royal Infirmary of Edinburgh)  11:40 - 11:50 Case study 6 <b>Therapeutic efficacy of Emicizumab in type 3 von Willebrand Disease</b> <a href="#">Dr Manmeet Singh Randhawa</a> (Speciality Registrar, Aberdeen Royal Infirmary)  11:50 - 12:00 Case study 7 <b>The FX of AL Amyloid</b> <a href="#">Dr Andrew Ross + Dr Rebecca Shaw</a> (Haematology SpR, Liverpool University Hospitals NHS Foundation Trust)  12:00 - 12:10 Case study 8 <b>A case report of relapse of immune-mediated thrombotic thrombocytopenic purpura after SARSCoV-2 vaccination</b> <a href="#">Dr Alasdair Gray</a> (ST7, Royal Infirmary of Edinburgh)  12:10 - 12:20 Discussion
11:20 – 12:20	<b>SESSION FIVE   Oral Communications 3</b> <i>Writers Suite - first floor</i> <b>Co-chairs   <a href="#">Dr Cedric Duval</a> + <a href="#">Dr Camille Ettelaie</a></b>
11:20 – 11:35	OC 10 Cell-based high throughput screening to identify compounds that inhibit the endothelial pro-thrombotic switch during cytokine storms <a href="#">Daisy Jones</a> (London)
11:35 – 11:50	OC 11 The TFPI $\alpha$ C-terminal tail is essential for the synergistic enhancement of TFPI $\alpha$ mediated inhibition of FXa by protein S and FV-short <a href="#">Magdalena Gierula</a> (London)
11:50 – 12:05	OC 12 Phenotypic features and genetic analysis of heterozygous and homozygous variants in glycoprotein Ib platelet alpha subunit (GP1BA), glycoprotein Ib platelet beta subunit (GP1BB) and glycoprotein IX (GP9) genes in inherited macrothrombocytopenia patients <a href="#">Catarina Isabel Loureiro Monteiro</a> (Porto, Portugal)
12:05 – 12:20	OC 13 A high degree of concordance in platelet activation between FcgRIIA stimuli <a href="#">Samantha J Montague</a> (Birmingham)

# Programme | Friday 27 January

12:20 – 13:15	<b>SESSION SIX   Summer students + Plenary five</b> <i>Fry Suite - ground floor</i> Co-chairs   <a href="#">Dr Catherine Bagot</a> + <a href="#">Dr Joanne Clark</a>
12:20 – 12:25	Investigating the haemostatic side effects of Pim kinase inhibitors <a href="#">Farieda Tarek Kamaleldin Saleh Kassim</a> (Manchester Metropolitan University)
12:25 – 12:30	Analysis of platelet transmission electron microscopy in a cohort of patients with a suspected platelet-based bleeding disorder <a href="#">Lily Redmond-Motteram</a> (University of Birmingham)
12:30 – 12:35	Investigating the expression of S100A8/Ag in platelets <a href="#">Caitlin Sullivan</a> (University of Birmingham)
12:35 – 12:40	The effect of polyphenols on fibrin clot structure and platelet procoagulant activity <a href="#">Lutale Metruth Kaselampao</a> (University of Leeds)
12:40 – 13:15	<b>Plenary 5</b> <b>Recent advances in haemophilia treatment</b> <a href="#">Dr Pratima Chowdary</a> , Royal Free London
13:15 – 14:10	Lunch   Networking   Exhibition <i>Writers Suite - 1st floor</i>
14:10 – 14:45	<b>SESSION SEVEN   Plenary six and Oral Communications 4</b> <i>Fry Suite - ground floor</i> Chair   <a href="#">Prof Helen Philippou</a>
14:10 – 14:45	<b>Plenary 6</b> <b>Microlyse - busting clots by targeting VWF</b> <a href="#">Dr Coen Maas</a> , University of Utrecht, The Netherlands
	<b>INVENT-VTE session + Oral Communications 4</b>
	Co-chairs   <a href="#">Prof Robert Ariens</a> + <a href="#">Dr Deepa Arachchillage</a>
14:45 – 15:00	<b>INVENT-VTE session</b> <a href="#">Dr Gill Lowe</a> (Birmingham)
15:00 – 15:15	<b>INVENT-VTE session</b> <a href="#">Dr Lara Roberts</a> (London)
15:15 – 15:30	OC 14 Mechanisms of platelet accumulation in an endothelium-coated elastic vein valve model of deep vein thrombosis <a href="#">Hosam Alden Baksamawi</a> (Birmingham)
15:30 – 15:45	OC 15 Fibrinolytic dysregulation in vaccine-induced immune thrombocytopenia and thrombosis (VITT) <a href="#">Megan Simpson</a> (Aberdeen)
15:45 – 16:00	OC 16 Thrombi from patients with acute myocardial infarction show fibrin film that increases with ischaemia duration <a href="#">Cedric Duval</a> (Leeds)
16:00 – 16:10	<b>Closing remarks and meeting close</b> <a href="#">Prof Nikki Mutch</a>

## Exhibitor and sponsor profiles



### AstraZeneca in the UK

A global pharmaceutical company with a major UK presence. Our purpose is to push the boundaries of science to deliver life-changing medicines. The best way we can help patients is to be science-led and share this passion with the scientific, healthcare and business communities of the UK.

**Contact name:** Andrew Furlong  
**Contact number:** +44 (0) 7557540970  
**Email:** [andrew.furlong@astrazeneca.com](mailto:andrew.furlong@astrazeneca.com)  
**Website:** [www.astrazeneca.co.uk](http://www.astrazeneca.co.uk)

## Exhibitor and sponsor profiles

# CSL Behring

### CSL Behring UK LTD

CSL Behring is a global leader in the plasma protein biotherapies industry. We research, develop, manufacture and market biotherapies, which are used to treat serious and rare conditions. These conditions include; coagulation (bleeding) disorders such as haemophilia and von Willebrand disease, immune deficiencies, rapid reversal of warfarin and to prevent haemolytic disease of the foetus and newborn. Users of our therapies rely on them for their quality of life and, in many cases, for life itself. Our commitment to improving the quality of life for those who use our therapies is evident in everything we do.

**Contact name:** Scott Wheway  
**Contact number:** +44 (0) 7384 895064  
**Email:** [scott.wheway@cslbehring.com](mailto:scott.wheway@cslbehring.com)  
**Website:** [www.cslbehring.co.uk](http://www.cslbehring.co.uk)

## Exhibitor and sponsor profiles



### LFB Biopharmaceuticals Ltd.

LFB Biopharmaceuticals Ltd. was created in 2015 to support the availability of LFB's biopharmaceutical products for serious and rare diseases to patients in the United Kingdom. The role of LFB Biopharmaceuticals is to facilitate the compliant provision of medicines to health care institutions and to support the medical needs of patients and healthcare professionals.

The therapeutic areas in which we currently provide medical and scientific support include:

- Immunology
- Haemostasis
- Intensive care

LFB Biopharmaceuticals is also responsible for communication to healthcare professionals for LFB products in the UK.

### A company committed to patients' lives

LFB is one of Europe's leading biopharmaceutical companies. Originally formed in 1994, today, we employ over 2,500 people, both in France and worldwide. We supply 15 biopharmaceuticals, including plasma derived and recombinant medicinal products, to approximately 30 countries treating hundreds of thousands of patients.

To support LFB's mission to supply treatment options to patients in the fields of immunology, haemostasis and intensive care, the company is undertaking a strategic transformation with the priority on industrial activities to support the continued growth of the company in France and internationally.

**Contact name:** Sanjeev Chand  
**Contact number:** +44 (0) 1462 558844  
**Email:** [sanjeev.chand@lfb-group.com](mailto:sanjeev.chand@lfb-group.com)  
**Website:** [www.cevenfacta.co.uk](http://www.cevenfacta.co.uk)

## Exhibitor and sponsor profiles

# octapharma®

### Octapharma Limited

Family owned since being established in 1983, Octapharma is a global healthcare company headquartered in Lachen, Switzerland. Our products are available in 118 countries and reach hundreds of thousands of patients every year. We focus on three therapeutic areas: haematology, immunotherapy and critical care.

Octapharma is one of the largest human protein product manufacturers. We develop and produce medicines based on human proteins from human cell lines and human plasma, sourced from our own plasma donation centres and other external sources.

[criticalcare.uk@octapharma.com](mailto:criticalcare.uk@octapharma.com)

**Contact name:** Andy Rowley  
**Contact number:** +44 (0) 7843063848  
**Email:** [Andy.rowley@octapharma.com](mailto:Andy.rowley@octapharma.com)  
**Website:** [www.octapharma.co.uk](http://www.octapharma.co.uk)



## Exhibitor and sponsor profiles



### Pfizer

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. In the UK, Pfizer has its business headquarters in Surrey and is a major supplier of medicines to the NHS.

To learn more about our commitments, please visit us at [www.pfizer.co.uk](http://www.pfizer.co.uk) or follow us on Twitter (@Pfizer\_UK), Facebook (@PfizerUK) and Instagram (@pfizeruk).

PP-UNP-GBR-1982| September 2022

## Exhibitor and sponsor profiles



### Quadraturech Diagnostics Ltd

Established in 1990, Quadraturech Diagnostics is committed to providing the highest quality medical diagnostic and research products. We are constantly looking for new and innovative products to expand our range of Haemostasis products.

We are a corporate member of the Institute of Biomedical Scientists and supporter of the British Society for Haemostasis and Thrombosis. We are a recognised supplier to the NHS, the Irish Health Service Executive (HSE), private laboratories, the UK pharmaceutical industry, and university research groups.

**Contact name:** Rosie Davies  
**Contact number:** +44 (0)3333 212 371  
**Email:** [Rosie.davies@quadraturech.co.uk](mailto:Rosie.davies@quadraturech.co.uk)  
**Website:** [www.quadraturech.co.uk](http://www.quadraturech.co.uk)  
**Twitter link:** <https://twitter.com/QuadraturechUK>  
**Facebook link:** <https://www.facebook.com/QuadraturechUK>  
**LinkedIn link:** <https://www.linkedin.com/company/quadraturech-diagnostics-ltd>

## Exhibitor and sponsor profiles



### Swedish Orphan Biovitrum Ltd

At Sobi, we are transforming life for people with rare diseases. As an international biopharmaceutical company, we provide access to innovative treatments in the areas of haematology, immunology and specialty care to improve people's lives.

PP-17561 Date of Prep: Jan 2023

**Contact number:** +44 (0) 1223 891854  
**Email:** [Mail.uk@sobi.com](mailto:Mail.uk@sobi.com)  
**Website:** [www.sobi-uk.co.uk](http://www.sobi-uk.co.uk)

## Exhibitor and sponsor profiles



### Stago UK Ltd

Stago is a global leader in coagulation, utilising over 40 years of experience to pioneer innovative solutions. Our purpose is to fulfil the needs of diagnostic laboratories, helping achieve the shared goal of improving patient wellbeing.

Successful collaborations through long-term partnerships place Stago as the trusted partner in haemostasis. Initiatives in multi-site data management solutions help our customers to simplify accreditation, facilitate quality processes and streamline patient management.

2023 sees the arrival of our new, next-generation, fully automated analysers for the core lab. We are also continuing our commitment to near-patient testing with a new, hand held, functional fibrinogen POC system.

**Contact name:** Haseena Halai / Katrina Ellis  
**Contact number:** +44 (0) 7768 304 105  
**Email:** [stago-uk@uk.stago.com](mailto:stago-uk@uk.stago.com)  
**Website:** <http://www.stago-uk.com>  
**Twitter link:** [Stago Official \(@Stago Official\) / Twitter](#)  
**LinkedIn link:** <https://www.linkedin.com/company/diagnostica-stago/?originalSubdomain=fr>

## Exhibitor and sponsor profiles



### **Sysmex UK Ltd.**

Sysmex UK Ltd are the distributors and support network for Sysmex automated haematology and coagulation diagnostic analysers, reagents and information systems for laboratories and healthcare facilities within the UK and Ireland. Sysmex UK also offers fully automated urinalysis workflow solutions on a premium level.

Sysmex UK Ltd are a subsidiary of the highly successful Sysmex Corporation currently ranked in the top 10 global in-vitro diagnostic companies. Since its formation in 1991, it has grown to become one of the UK's leading diagnostic suppliers with a reputation for high quality products, service, and reliability.

With an ever-increasing demand and diminishing resources, the healthcare market is faced with the need to improve their efficiency within the laboratories. Sysmex are constantly adapting to help our customers to meet these needs, expanding the boundaries of diagnostic science to develop new systems whilst providing an unrivalled level of service and support along the way.

**Contact name:** Yuliia Shevchenko  
**Contact number:** 0333 320 3460  
**Email:** [info@sysmex.co.uk](mailto:info@sysmex.co.uk)  
**Website:** [www.sysmex.co.uk](http://www.sysmex.co.uk)  
**LinkedIn link:** <https://www.linkedin.com/company/sysmex-uk>

## Exhibitor and sponsor profiles

# werfen

### Werfen

Werfen is a growing, family-owned, innovative company founded in 1966 in Barcelona, Spain.

We are a worldwide leader in specialized diagnostics in the areas of Hemostasis, Acute Care Diagnostics and Autoimmunity. Through our Original Equipment Manufacturing (OEM) business line, we research, develop and manufacture customized assays and biomaterials.

We operate directly in 30 countries, and in more than 100 territories through distributors. Our Headquarters and Technology Centers are located in the US and Europe. Worldwide sales exceed \$2 billion annually, and our workforce is more than 5,000 strong.

**Contact name:** Michelle Clayton  
**Contact number:** +44 (0) 1925 810 141  
**Email:** [salesuk@werfen.com](mailto:salesuk@werfen.com)  
**Website:** [www.werfen.co.uk](http://www.werfen.co.uk)  
**LinkedIn link:** [Werfen UK | LinkedIn](#)

## Exhibitor and sponsor profiles



### **FUJIMORI KOGYO CO.,LTD.**

#### **Fujimori Kogyo Co., Ltd. (ZACROS)**

Fujimori Kogyo, also known as ZACROS, has been providing unique packaging solutions to various industries since 1914. In 1988, we became one of the first companies to receive FDA approval for plastic drug solution packaging materials. Our single-use bag series for bio-pharmaceuticals supports the R&D process through production of vaccines, antibody drugs and even regenerative medicine.

Our *in vitro* diagnostics system 'T-TAS®01' is an automated microchip flow chamber system developed for the assessment of the thrombus formation process under flow conditions which mimics arterial blood flow. It is obtained CE marking in 2019 as well as FDA clearance in 2020, and that is expected to improve the quality of medical care in the hemostasis field.

**Contact name:** Ryoji Karinaga  
**Contact number:** +81 (0) 80 4443 1700  
**Email:** [ttas-info@zacros.co.jp](mailto:ttas-info@zacros.co.jp)  
**Website:** <https://www.t-tas.info/>